Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription Articles published in Radiother Oncol Retrieve available abstracts of 81 articles: HTML format

Single Articles

March 2026
1. CANHA-BORGES A, Nunes B, Estevao D, Fernandes R, et al
   Radiotherapy induces layer-specific molecular and ultrastructural alterations in triple-negative breast cancer spheroids.
   Radiother Oncol. 2026 Mar 30:111518. doi: 10.1016/j.radonc.2026.111518.
   PubMed     Abstract available
   
   
   February 2026
2. SHAH I, Lucas S, Walsh R, Osman I, et al
   Artificial intelligence model for cardiovascular disease risk prediction in breast cancer patients using electronic health records and computed tomography scans.
   Radiother Oncol. 2026 Feb 25:111455. doi: 10.1016/j.radonc.2026.111455.
   PubMed     Abstract available
   
   
   
3. ALKNER S, Appelgren M, Szulkin R, Wieslander E, et al
   Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC.
   Radiother Oncol. 2026;218:111454.
   PubMed     Abstract available
   
   
   
4. MACHIELS M, Kaidar-Person O, Marta GN, Meattini I, et al
   Reconsidering the role of PMRT in low to intermediate risk breast cancer: Applying results from previous standards of treatment in the current multimodal practice.
   Radiother Oncol. 2026;217:111416.
   PubMed     Abstract available
   
   
   January 2026
5. MINK VAN DER MOLEN DR, Batenburg MCT, van 't Westeinde T, Houweling AC, et al
   Acute toxicity and quality of life after 5-fraction versus 15-fraction adjuvant radiotherapy following conventional or oncoplastic breast-conserving surgery - a real-world prospective cohort study.
   Radiother Oncol. 2026;214:111310.
   PubMed     Abstract available
   
   
   
6. SALVESTRINI V, Marrazzo L, Barletta G, Becherini C, et al
   Cardiac safety of ultra-hypofractionated whole breast irradiation: Results from the SAFE-FORWARD observational prospective cohort study.
   Radiother Oncol. 2026;214:111267.
   PubMed     Abstract available
   
   
   
7. HOVENIER R, Huele EH, Bindels BJJ, van Oss A, et al
   Pain response of patients treated with radiotherapy for painful bone metastases between 2013 and 2024 - An analysis of the prospective real-world PRESENT cohort.
   Radiother Oncol. 2026;214:111263.
   PubMed     Abstract available
   
   
   
8. BRION T, Balde M, Allodji R, Rossier C, et al
   Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial.
   Radiother Oncol. 2026;214:111202.
   PubMed     Abstract available
   
   
   
9. LICHTER KE, Asaro A, Qureshi MM, Truong MT, et al
   The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.
   Radiother Oncol. 2026;214:111161.
   PubMed     Abstract available
   
   
   
10. JAIKUNA T, Wilson F, Anandadas C, Azria D, et al
    Unveiling regions associated with acute and late breast side-effects from breast radiotherapy using voxel-wise image-based data mining analysis.
    Radiother Oncol. 2026;214:111230.
    PubMed     Abstract available
    
    
    
11. ATTILI A, Algranati C, Cianchetti M, Giacomelli I, et al
    A dedicated MKM-based radiobiological model for secondary cancer estimation in charged particle radiotherapy: An application in lymphomas and breast proton therapy.
    Radiother Oncol. 2026;214:111229.
    PubMed     Abstract available
    
    
    December 2025
12. MALONE C, Ryan S, Nicholson J, Brennan S, et al
    From rugged ridges to radiotherapy ROIs: Translating topographical metrics to Surface-Guided Radiation Therapy regions of Interest in radiotherapy.
    Radiother Oncol. 2025;213:111173.
    PubMed     Abstract available
    
    
    November 2025
13. NG S, Kirby AM, Kilburn LS, Griffin C, et al
    Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5?years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials.
    Radiother Oncol. 2025 Nov 27:111301. doi: 10.1016/j.radonc.2025.111301.
    PubMed     Abstract available
    
    
    
14. THOMSEN MS, Offersen BV
    Response to comment on "Quality assessment of 2705 treatment plans in the randomised Danish breast cancer Group Skagen trial 1".
    Radiother Oncol. 2025 Nov 19:111286. doi: 10.1016/j.radonc.2025.111286.
    PubMed    
    
    
    
15. GAO C, Wang L, Ma K, Chen Y, et al
    Comment on "Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1".
    Radiother Oncol. 2025 Nov 14:111285. doi: 10.1016/j.radonc.2025.111285.
    PubMed    
    
    
    
16. BILSKI M, Kuncman L, Orzechowska M, Cisek P, et al
    Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study.
    Radiother Oncol. 2025;214:111280.
    PubMed     Abstract available
    
    
    October 2025
17. ZAMAGNI A, Luis AM, Mjaaland I, Chirila ME, et al
    ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives.
    Radiother Oncol. 2025 Oct 27:111236. doi: 10.1016/j.radonc.2025.111236.
    PubMed     Abstract available
    
    
    
18. BELARDO A, Dimayuga KB, Perna L, Fodor A, et al
    Density and volume of cardiac calcifications detected on planning CT predicts cardiotoxicity after hypo-fractionated whole breast Radiotherapy.
    Radiother Oncol. 2025;211:111098.
    PubMed     Abstract available
    
    
    
19. NG S, Kilburn LS, Kirby AM, Griffin C, et al
    Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial.
    Radiother Oncol. 2025;211:111056.
    PubMed     Abstract available
    
    
    September 2025
20. JOSEPH K, Ademola A, Zebak J, Singh A, et al
    Adjuvant radiotherapy alone, an effective treatment option for early-stage low- risk breast cancer in women over 50: results from a population based cohort study using a Canadian provincial database.
    Radiother Oncol. 2025 Sep 29:111175. doi: 10.1016/j.radonc.2025.111175.
    PubMed     Abstract available
    
    
    
21. THOMSEN MS, Lorenzen EL, Alsner J, Krogh SL, et al
    Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1.
    Radiother Oncol. 2025 Sep 15:111142. doi: 10.1016/j.radonc.2025.111142.
    PubMed     Abstract available
    
    
    
22. WANG DQ, Yan L, Wu HF, Zhong YH, et al
    Prospective cohort study to validate esophageal dose constraints and predictive models for esophagitis in patients with breast cancer undergoing hypofractionated regional nodal radiotherapy.
    Radiother Oncol. 2025;212:111120.
    PubMed     Abstract available
    
    
    August 2025
23. OLIVEROS S, Goyal A, Dodwell D
    The impact of radiotherapy on trials of axillary management in early breast cancer.
    Radiother Oncol. 2025 Aug 6:111054. doi: 10.1016/j.radonc.2025.111054.
    PubMed     Abstract available
    
    
    
24. NELISSEN SH, Young-Afat DA, Bongard HJGDVD, Coert JH, et al
    Neoadjuvant radiotherapy and immediate breast reconstruction: A systematic review of literature of the last decade.
    Radiother Oncol. 2025;209:110991.
    PubMed     Abstract available
    
    
    
25. KAIDAR-PERSON O, Poortmans P, Meattini I, Tramm T, et al
    An additional peril of pathologic complete response.
    Radiother Oncol. 2025;209:110962.
    PubMed     Abstract available
    
    
    
26. HORBERGER F, Petersson K, Ceberg S, Back S, et al
    Investigating the therapeutic potential of FLASH radiotherapy - a treatment planning study.
    Radiother Oncol. 2025;209:110947.
    PubMed     Abstract available
    
    
    July 2025
27. PUTORA PM, Henke G, Bese N, Boersma L, et al
    What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?
    Radiother Oncol. 2025 Jul 20:111055. doi: 10.1016/j.radonc.2025.111055.
    PubMed     Abstract available
    
    
    
28. BOERSMA LJ, Hessels A, Roberti S, Seravall E, et al
    Selection of patients for proton therapy to reduce risk of second primary lung and breast cancer.
    Radiother Oncol. 2025 Jul 4:110998. doi: 10.1016/j.radonc.2025.110998.
    PubMed     Abstract available
    
    
    
29. GUCKENBERGER M, Wilke L, Billiet C, Rogers S, et al
    Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial.
    Radiother Oncol. 2025;208:110940.
    PubMed     Abstract available
    
    
    June 2025
30. BRUNT AM, Cafferty FH, Wheatley D, Sydenham MA, et al
    Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.
    Radiother Oncol. 2025;207:110915.
    PubMed     Abstract available
    
    
    
31. NIELSEN AWM, Thorsen LBJ, Ozcan D, Matthiessen LW, et al
    Local recurrence with and without a tumour-bed boost: A post-hoc analysis of the DBCG IMN2 study.
    Radiother Oncol. 2025;207:110905.
    PubMed     Abstract available
    
    
    May 2025
32. PRADES-SAGARRA E, Geurts FAP, Biemans R, Lieuwes NG, et al
    The radiosensitizing effect of Caffeic Acid Phenethyl Ester in breast cancer is dependent on p53 status.
    Radiother Oncol. 2025;209:110945.
    PubMed     Abstract available
    
    
    
33. KIM S, Jeon SH, Kim Y, Park N, et al
    TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model.
    Radiother Oncol. 2025 May 11:110932. doi: 10.1016/j.radonc.2025.110932.
    PubMed     Abstract available
    
    
    
34. CALUWE A, Bellal S, Cao K, Peignaux K, et al
    Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.
    Radiother Oncol. 2025;206:110836.
    PubMed     Abstract available
    
    
    March 2025
35. BRION T, Ghodssighassemabadi R, Auzac G, Kirova Y, et al
    Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.
    Radiother Oncol. 2025;207:110849.
    PubMed     Abstract available
    
    
    
36. VINCENZI MM, Cicchetti A, Castriconi R, Mangili P, et al
    Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques.
    Radiother Oncol. 2025;204:110700.
    PubMed     Abstract available
    
    
    February 2025
37. BYUN HK, Kim H, Son J, Cho Y, et al
    Impact of bra application in breast cancer radiotherapy: A pilot prospective randomized trial.
    Radiother Oncol. 2025;206:110785.
    PubMed     Abstract available
    
    
    January 2025
38. CHUFAL KS, Ahmad I, Miller AA, Bajpai R, et al
    Machine learning model for predicting DIBH non-eligibility in left-sided breast cancer radiotherapy: Development, validation and clinical impact analysis.
    Radiother Oncol. 2025;205:110764.
    PubMed     Abstract available
    
    
    
39. EOM A, Kirkwood D, Pond G, Hodgson N, et al
    Radiation therapy and immigration status in women with breast cancer.
    Radiother Oncol. 2025 Jan 31:110774. doi: 10.1016/j.radonc.2025.110774.
    PubMed     Abstract available
    
    
    
40. YEH J, Tacey M, Harris B, Lau E, et al
    Stabilised hyaluronic acid gel marker versus surgical clips for tumour bed delineation in breast cancer radiotherapy using MRI-simulation.
    Radiother Oncol. 2025;205:110749.
    PubMed     Abstract available
    
    
    
41. MOSHE N, Haisraely O, Globus O, Faermann R, et al
    Breast cancer outcomes after skin- and nipple-sparing mastectomy in BRCA pathogenic mutation carriers versus non-BRCA carriers.
    Radiother Oncol. 2025;205:110710.
    PubMed     Abstract available
    
    
    
42. REFSGAARD L, Buhl ES, Nielsen AWM, Thomsen MS, et al
    Quality assurance of internal mammary node irradiation in the DBCG IMN2 study.
    Radiother Oncol. 2025;202:110600.
    PubMed     Abstract available
    
    
    
43. CHUNG CV, Khan MS, Olanrewaju A, Pham M, et al
    Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sites.
    Radiother Oncol. 2025;202:110609.
    PubMed     Abstract available
    
    
    December 2024
44. REFSGAARD L, Holm Milo ML, Buhl ES, Jensen JM, et al
    The effect of coronary artery calcifications and radiotherapy on the risk of coronary artery disease in high-risk breast cancer patients in the DBCG RT-Nation cohort.
    Radiother Oncol. 2024 Dec 24:110705. doi: 10.1016/j.radonc.2024.110705.
    PubMed     Abstract available
    
    
    
45. LATORRE-MUSOLL A, Oses G, Antelo G, Serrano-Rueda S, et al
    Transit-guided radiation therapy: a novel patient monitoring approach.
    Radiother Oncol. 2024;201:110580.
    PubMed     Abstract available
    
    
    
46. THOMSEN MS, Alsner J, Lutz CM, Berg M, et al
    Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost.
    Radiother Oncol. 2024;201:110574.
    PubMed     Abstract available
    
    
    
47. GUINOT JL, Gutierrez-Miguelez C, Meszaros N, Gonzalez-Perez V, et al
    Five-year results of the very accelerated partial breast irradiation VAPBI phase I-II GEC-ESTRO trial.
    Radiother Oncol. 2024;201:110543.
    PubMed     Abstract available
    
    
    November 2024
48. KUBECZKO M, Gabrys D, Rembak-Szynkiewicz J, Graupner D, et al
    Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.
    Radiother Oncol. 2024 Nov 18:110639. doi: 10.1016/j.radonc.2024.110639.
    PubMed     Abstract available
    
    
    
49. BUHL ES, Refsgaard LH, Al-Rawi SA, Andersen K, et al
    Population based audit of heart radiation doses in 6925 high-risk breast cancer patients from the Danish breast cancer group RT Nation study.
    Radiother Oncol. 2024 Nov 16:110643. doi: 10.1016/j.radonc.2024.110643.
    PubMed     Abstract available
    
    
    
50. VAN SCHIE P, Huisman RG, Wiersma T, Knegjens JL, et al
    Local control and toxicity after stereotactic radiotherapy in brain metastases patients and the impact of novel systemic treatments.
    Radiother Oncol. 2024;200:110540.
    PubMed     Abstract available
    
    
    
51. BOUTRY C, Moreau NN, Jaudet C, Lechippey L, et al
    Machine learning and deep learning prediction of patient specific quality assurance in breast IMRT radiotherapy plans using Halcyon specific complexity indices.
    Radiother Oncol. 2024;200:110483.
    PubMed     Abstract available
    
    
    
52. SMINE Z, Poeta S, De Caluwe A, Desmet A, et al
    Automated segmentation in planning-CT for breast cancer radiotherapy: A review of recent advances.
    Radiother Oncol. 2024;202:110615.
    PubMed     Abstract available
    
    
    October 2024
53. DE ROSE F, Carmen De Santis M, Lucidi S, Ray Colciago R, et al
    Dose constraints in breast cancer radiotherapy. A critical review.
    Radiother Oncol. 2024 Oct 18:110591. doi: 10.1016/j.radonc.2024.110591.
    PubMed     Abstract available
    
    
    
54. KAIDAR-PERSON O, Ratosa I, Franco P, Masiello V, et al
    The Assisi think tank focus review on postoperative radiation for lobular breast cancer.
    Radiother Oncol. 2024 Oct 10:110573. doi: 10.1016/j.radonc.2024.110573.
    PubMed     Abstract available
    
    
    
55. BUHL ES, Lorenzen EL, Refsgaard L, Nielsen AWM, et al
    Development and comprehensive evaluation of a national DBCG consensus-based auto-segmentation model for lymph node levels in breast cancer radiotherapy.
    Radiother Oncol. 2024;201:110567.
    PubMed     Abstract available
    
    
    
56. ALI T, Vellengara M, Albalushi FY, Basheer R, et al
    Deep Inspiration breath Hold facilitates surgical cavity registration on cone beam imaging for Partial breast irradiation.
    Radiother Oncol. 2024;199:110471.
    PubMed     Abstract available
    
    
    
57. ALONGI F, Nicosia L, Ricardi U, Scorsetti M, et al
    Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E(2)-RADIatE OligoCare cohort.
    Radiother Oncol. 2024;199:110466.
    PubMed     Abstract available
    
    
    
58. JOHNSON PB, Mamalui M, Brodin P, Janssens G, et al
    Secondary cancer risk in six anatomical sites when using PAT, IMPT, and VMAT/IMRT radiotherapy.
    Radiother Oncol. 2024;199:110421.
    PubMed     Abstract available
    
    
    September 2024
59. KAIDAR-PERSON O, Boersma L, De Brouwer P, Weltens C, et al
    The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies.
    Radiother Oncol. 2024 Sep 26:110563. doi: 10.1016/j.radonc.2024.110563.
    PubMed     Abstract available
    
    
    
60. GROOT KOERKAMP M, Stijnman P, Houweling A, Zachiu C, et al
    Automated dose evaluation on daily cone-beam computed tomography for breast cancer patients.
    Radiother Oncol. 2024;200:110541.
    PubMed     Abstract available
    
    
    August 2024
61. LAVIGNE D, Hijal T, Vavassis P, Guilbert MC, et al
    Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: Oncologic outcome, toxicity and cosmesis of the SPORT-DS phase I trial.
    Radiother Oncol. 2024;200:110515.
    PubMed     Abstract available
    
    
    
62. MAHMOUD D, Yassa M, Alvarado L, Lambert C, et al
    Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study.
    Radiother Oncol. 2024;200:110510.
    PubMed     Abstract available
    
    
    
63. KIM Y, Jeon SH, Kim S, Kang MH, et al
    In vitro-irradiated cancer vaccine enhances anti-tumor efficacy of radiotherapy and PD-L1 blockade in a syngeneic murine breast cancer model.
    Radiother Oncol. 2024;200:110480.
    PubMed     Abstract available
    
    
    
64. ALKNER S, Wieslander E, Lundstedt D, Berg M, et al
    Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
    Radiother Oncol. 2024;197:110372.
    PubMed     Abstract available
    
    
    
65. FRANCESCHINI D, Teriaca MA, Mancosu P, Bertolini A, et al
    Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases.
    Radiother Oncol. 2024;197:110335.
    PubMed     Abstract available
    
    
    July 2024
66. CHUN SJ, Kim K, Kim YB, Paek SH, et al
    Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery.
    Radiother Oncol. 2024;199:110461.
    PubMed     Abstract available
    
    
    
67. BOERSMA LJ, Bijker N, Stam MR
    Reporting breast cancer radiation therapy details in studies and daily practice: Nice-to-have or a must-have?
    Radiother Oncol. 2024 Jul 17:110429. doi: 10.1016/j.radonc.2024.110429.
    PubMed    
    
    
    
68. OVERGAARD J, Ccm Hulshof M, Dahl O, Arcangeli G, et al
    ESHO 1-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of locally advanced breast carcinoma. A randomized multicenter study by the European Society for Hyperthermic Oncology.
    Radiother Oncol. 2024;196:110313.
    PubMed     Abstract available
    
    
    June 2024
69. SONG YC, Chen SY, Zhao XR, Jing H, et al
    Prognostic value of lymphocytes in patients with breast cancer receiving radiotherapy after breast-conserving surgery: A post hoc analysis of a phase III randomized trial.
    Radiother Oncol. 2024 Jun 17:110390. doi: 10.1016/j.radonc.2024.110390.
    PubMed     Abstract available
    
    
    
70. CACHO-DIAZ B, Valdes-Ferrer SI, Chavez-MacGregor M, Salmeron-Moreno K, et al
    Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer.
    Radiother Oncol. 2024 Jun 9:110379. doi: 10.1016/j.radonc.2024.110379.
    PubMed     Abstract available
    
    
    
71. CHRIST SM, Alongi F, Ricardi U, Scorsetti M, et al
    Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E(2)-RADIatE OligoCare study.
    Radiother Oncol. 2024;195:110235.
    PubMed     Abstract available
    
    
    May 2024
72. HOGSBJERG KW, Offersen BV
    Author's response to Letter-to-the-Editor from Chang JS. concerning: "Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial".
    Radiother Oncol. 2024;197:110351.
    PubMed     Abstract available
    
    
    
73. CHEN F, Zhou P, Ren G, Lee EKW, et al
    Interpretable deep learning insights: Unveiling the role of 1 Gy volume on lymphopenia after radiotherapy in breast cancer.
    Radiother Oncol. 2024;197:110333.
    PubMed     Abstract available
    
    
    
74. HANNOUN-LEVI JM, Gimeno Morales M, Gal J, Anchuelo J, et al
    Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort.
    Radiother Oncol. 2024;194:110217.
    PubMed     Abstract available
    
    
    
75. CICCHETTI A, Mangili P, Fodor A, Gabellini MGU, et al
    Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy.
    Radiother Oncol. 2024;194:110183.
    PubMed     Abstract available
    
    
    April 2024
76. REFSGAARD L, Skarso Buhl E, Yates E, Maae E, et al
    Evaluating Danish Breast Cancer Group locoregional radiotherapy guideline adherence in clinical treatment data 2008-2016: The DBCG RT Nation study.
    Radiother Oncol. 2024 Apr 25:110289. doi: 10.1016/j.radonc.2024.110289.
    PubMed     Abstract available
    
    
    March 2024
77. FRANCESCHINI D, Franzese C, Comito T, Ilieva MB, et al
    Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.
    Radiother Oncol. 2024;195:110240.
    PubMed     Abstract available
    
    
    
78. HUIJSKENS S, Granton P, Fremeijer K, van Wanrooij C, et al
    Clinical practicality and patient performance for surface-guided automated VMAT gating for DIBH breast cancer radiotherapy.
    Radiother Oncol. 2024 Mar 14:110229. doi: 10.1016/j.radonc.2024.110229.
    PubMed     Abstract available
    
    
    
79. KUBECZKO M, Jarzab M, Gabrys D, Krzywon A, et al
    Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].
    Radiother Oncol. 2024;194:110188.
    PubMed    
    
    
    
80. HOGSBJERG KW, Maae E, Nielsen MH, Stenbygaard L, et al
    Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial.
    Radiother Oncol. 2024 Mar 3:110195. doi: 10.1016/j.radonc.2024.110195.
    PubMed     Abstract available
    
    
    
81. GIMENO-MORALES M, Martinez-Monge R, Martinez-Lage A, Jablonska PA, et al
    Long-term results of intraoperative multicatheter breast implant (IOMBI) for accelerated partial breast irradiation (APBI) on early breast cancer patients.
    Radiother Oncol. 2024;194:110193.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum